

2 **Controlled Release of Enrofloxacin by Vanillin-Crosslinked** 3 **Chitosan-Polyvinyl Alcohol Blends**

4 **Ilkay Karakurt¹, Kadir Ozaltin¹, Elif Vargun^{1,2}, Liliana Kucerova¹, Pavol Suly¹, Evghenii**
5 **Harea^{1,3}, Antonín Minařík^{1,3}, Kateřina Štěpánková¹, Marian Lehocky^{1,3}*, Petr Humpolíček^{1,3},**
6 **Alenka Vesel⁴, Miran Mozetic⁴**

8 ¹Centre of Polymer Systems, University Institute, Tomas Bata University in Zlin, Trida Tomase Bati
9 5678, 760 01 Zlin, Czech Republic

10 ²Department of Chemistry, Mugla Sitki Kocman University, Kotekli, 48000, Mugla, Turkey

11 ³Faculty of Technology, Tomas Bata University in Zlín, Vavreckova 275, 76001 Zlín, Czech Republic

12 ⁴Department of Surface Engineering, Jozef Stefan Institute, Jamova cesta 39, 1000 Ljubljana, Slovenia

13 ykarakurt@utb.cz (I.K.); ozaltin@utb.cz (K.O.); vargun@utb.cz (E.V.); l7_kucerova@utb.cz (L.K);
14 suly@utb.cz (P.S); harea@utb.cz (E.H); minarik@utb.cz (A.M.); k1_stepankova@utb.cz (K.Š);
15 humpolicek@utb.cz (P.H); alenka.vesel@ijs.si (A.V); miran.mozetic@ijs.si (M.M)

16 * Correspondence: lehocky@post.cz; Tel.: +420-608-616-048

17 Received: date; Accepted: date; Published: date

18 **Abstract:** In transdermal drug delivery applications uniform drug distribution and sustained release
19 are of great importance to decrease the side effects. In this direction in the present research, vanillin
20 crosslinked chitosan (CS) and polyvinyl alcohol (PVA) blend based matrix-type transdermal system
21 was prepared by casting and drying of aqueous solutions for local delivery of enrofloxacin (ENR) drug.
22 Subsequently, the properties including the morphology, chemical structure, thermal behavior, tensile
23 strength, crosslinking degree, weight uniformity, thickness, swelling and drug release of the CS-PVA
24 blend films before and after crosslinking were characterized. *In vitro* drug release profiles showed the
25 sustained release of ENR by the incorporation of vanillin as a crosslinker into the CS-PVA polymer
26 matrix. Furthermore, the release kinetic profiles revealed that the followed mechanism for all samples
27 was Higuchi and the increase of vanillin concentration in the blend films resulted in the change of
28 diffusion mechanism from anomalous transport to Fickian diffusion. Overall, the obtained results
29 suggest that the investigated vanillin crosslinked CS-PVA matrix-type films are potential candidates
30 for transdermal drug delivery system.

31 **Keywords:** Chitosan, Vanillin, Crosslinking, Solvent casting, Drug-polymer solubility, Controlled
32 drug release, Transdermal delivery


33

34 **1. Introduction**

35 Among several routes of drug delivery applications, the transdermal system has accepted as potential
36 non-invasive routes of drug administration due to its attractive advantages. The main advantages of this
37 non-conventional drug delivery system include the possibility of pain-free therapy, prevention of the
38 pre-systemic metabolism, targeted delivery, providing constant blood levels and avoidance of first-pass
39 metabolism [1,2]. Transdermal systems have designed to deliver the active substances into the systemic
40 circulation via the dermal route in a controlled manner [3]. In such delivery systems, controlled drug
41 release allows distribution of the active substances at a predetermined rate locally or for over an
42 extended period which is significant to ensure a therapeutic concentration in the bloodstream [4,5]. In
43 the case of the doses above this therapeutic index, drugs elicit toxicity against patients and below the

44 appropriate amount, desired therapeutic effect would not be achieved [6]. Together with the controlled
45 release characteristics, transdermal delivery also ensures the protection of the pharmacological
46 properties of the drug when loaded in a polymer matrix [7].

47 In recent years, substantial research has been reported to produce a biopolymer-based potential
48 transdermal delivery device for effective transportation of drug molecules across the skin [8]. However,
49 the skin acts as a primary barrier for drug penetration due to the presence of hydrophobic lipid
50 membrane on the outermost layer (stratum corneum) [9]. This layer consists of dead keratin filled cells
51 (ie. corneocytes) which are surrounded by continuous lipid bilayers [10]. In order to reach systemic
52 circulation via penetration, an active substance has possible pathways according to the lipid-protein-
53 partitioning theory [11]. As shown in Figure 1, in the intercellular route drug molecules are transferred
54 around the corneocytes while in the intracellular way delivery into the bloodstream occurs passing
55 through the cell membrane. Regarding a variety of approaches, to be able to deliver the active
56 substances into the systemic circulation, polymeric materials are widely studied due to their remarkable
57 effect on local skin penetration.



58

59 **Figure 1.** Pathways of permeation through skin and the permeation-enhancing effect of CS


60 Transdermal drug delivery devices originated from synthetic or natural or both polymers typically
61 provide the necessary structural support for diffusion and drug administration through skin. Plenty of
62 works report on the literature potential transdermal patches fabricated from several polymers (pure or
63 blend) using different processing techniques such as hydrogels, microspheres, nanoparticles and
64 nanofibers [12]. Among these, preparing polymer films by solvent casting technique has been favorably
65 applied due to easy processing, reproducibility, cost-effective production and stability properties [13].
66 In this regard, polysaccharides are a prominent class of biopolymers used to design matrix-type systems
67 for transdermal delivery applications with controllable chemical and mechanical properties [14].

68 Chitosan (CS), a derivative of the biopolymer chitin, has been widely processed in the biomedical field
69 as a good film-forming matrix [15]. Besides wound healing and tissue engineering applications, CS
70 shows promising features to be used as an auxiliary agent in drug delivery systems owing to its unique
71 properties, including biodegradability, biocompatibility, permeation enhancement, hemostatic
72 capability, bactericidal and fungicidal activity [16-18]. These properties are closely related to the
73 molecular weight as well as the primary amino groups of CS which make it a unique biomaterial among
74 all the other biodegradable polymers by exhibiting a cationic character [19]. So this positively charged
75 linear structure enables the interaction with the negatively charged phospholipid and reversibly alters
76 the physicochemical nature in lipid bilayer of the stratum corneum to enhance the drug diffusion into

77 deeper layer of skin [20]. Moreover, it is known that modification of these amino and hydroxyl groups
78 on the CS structure could impart improved properties and particular biological functions such as
79 solubility, mucoadhesion, and bio-adhesivity [21]. There are several ways can be used to alter the CS
80 backbone with the purpose of tailoring the network structure of the polysaccharide to suit specific
81 applications.

82 Crosslinking is a well-known and proven technique to modify the CS backbone and to reduce segment
83 mobility in the polymer chains causing a three-dimensional network structure [22]. Crosslinking affects
84 the hydrophilicity, swelling behavior, biodegradation rate, stability, dispersivity, controlled release,
85 drug targeting and mechanical properties [23-25]. Some of the crosslinkers to improve these properties
86 are glutaraldehyde, formaldehyde, tripolyphosphate and glyoxal [26,27]. However, these agents present
87 several problems related to their potential side effects and environmental impact which limit their usage
88 as crosslinkers in pharmacological applications. Within this context, more attention has been paid on
89 green and natural crosslinking agents, such as plant extracts (polyphenols and aldehyde compounds)
90 [28].

91 Vanillin, which exists in seedpods of vanilla (*Vanilla planifolia*), is one of the most prevalent additives
92 and widely used as a flavoring and preservative agent in practical applications such as food, beverages,
93 perfumery and pharmaceutical industry [29-31]. It is a significant bio-based monomer and exhibits
94 bioactive properties such as antitumor, anti-inflammatory, antioxidant and antimutagenic activities
95 [32,33]. The aldehyde group of vanillin, which leads to identifying it as a natural crosslinker, constitutes
96 a Schiff-base bond with the amino groups of CS, and also the hydroxyl group of this crosslinker can
97 form a hydrogen bond with the amino or hydroxyl groups of another CS molecule (Figure 2) [31]. With
98 the formation of these hybrid network structure, the molecular mobility of the drug molecules in the CS
99 polymer matrix is restricted and the stability, dispersivity as well as the release control of the drug are
100 improved in the local delivery system [34,35].



101

102

Figure 2. Schematic representation of Schiff base formation between CS and vanillin

103 However, the natural brittleness of most of the polysaccharide-based films (i.e. CS) limits their
104 applications, and to overcome this limitation using a biocompatible and non-antigenic copolymer, like
105 PVA, to be blended with CS can be an effective strategy. The proper amount of PVA contributes to
106 improve the flexibility and the elongation of the CS films and eliminate the necessity to use plasticizers
107 [36].

108 So far, the crosslinking of CS with vanillin for the drug delivery purpose investigated in the literature.
109 Although considerable attempts devoted to improving the sustained release of several drugs
110 incorporated into vanillin crosslinked CS microspheres [37] and nanoparticles [32,38], less attention
111 has been paid to vanillin crosslinked films to improve drug-polymer solubility and controlled release.

112 Drug-polymer solubility may represent the essential parameter for the uniform distribution and
113 sustained release of drugs [39]. Insufficient drug-polymer solubility may lead to drug nucleation of
114 crystalline form and accelerate the crystal growth [40]. For drug release applications, this behavior may
115 ultimately result in reduced product performance, physical stability issues, and lower bioavailability
116 which will neutralize the advantages of transdermal delivery systems [41,42]. One way of enhancing
117 drug-polymer solubility of poorly soluble drugs in the solid dispersions is the restriction of molecular
118 mobility, thus preventing uncontrolled drug recrystallization [43]. In this study, vanillin used as a
119 crosslinker to create a network structure that can limit the segment mobility with the aim of homogenous
120 drug dispersivity and controlled release.

121 Overall, the main aim of this study is to prepare polymer blend films using high molecular weight-CS
122 and PVA (CS-PVA) and to evaluate the efficacy of vanillin as a crosslinking agent on drug release
123 studies. To test the drug release behavior of the films, ENR was used as a poorly-water soluble model
124 drug. Also, this combination in matrix-type transdermal system prepared without using any plasticizer
125 or permeation enhancer was not studied well according to the past literature. The physicochemical and
126 mechanical properties of the prepared films were analyzed by Scanning electron microscopy (SEM),
127 Fourier transform infrared spectroscopy (FTIR), Atomic Force Microscopy (AFM), Laser Scanning
128 Confocal Microscope (LSCM), X-ray photoelectron spectroscopy (XPS) and Thermal gravimetric
129 analysis (TGA). Furthermore, the degree of crosslinking, swelling properties and the release kinetics of
130 the polymer blends were also investigated by the ninhydrin assay, measuring mass change in dry-
131 swollen states of films, and 'sample and separate *in vitro* method', respectively. The possible outcomes
132 from the study revealed that vanillin crosslinked CS-PVA blend films can sustainably release and
133 stabilize ENR so as to achieve better therapeutic efficacy which show promising potential to perform
134 as transdermal drug delivery systems.


135 2. Materials and Methods

136 2.1. Materials

137 High molecular weight CS (310-375 kDa) with 75-85% degree of deacetylation, vanillin (99%) and
138 ninhydrin were purchased from Sigma Aldrich (Prague, Czech Republic). Acetic acid (99.8%) was
139 supplied from Microchem (Pezinok, Slovakia), ENR (Mw 395 Da) and PVA 8-88 (Mw ~ 67,000,
140 degree of hydrolysis 86.7–88.7 mol%) were obtained from Fluka Bio-Chemika (Steinheim, Germany).
141 Ethanol (99.8%, spectral) was obtained from Riedel-de Haën (Seelze, Germany), and phosphate-
142 buffered saline was obtained from Biosera (Prague, Czech Republic). All the reagents were analytical
143 grade.

144 2.2. Preparation of Polymer Films

145 The high molecular weight CS solution with a concentration of 1%(w/v) was prepared by dissolving
146 CS in aqueous acetic acid solution (2% v/v) under magnetic stirring at 50 °C for 2h until its complete
147 dissolution. Then the crosslinking agent solutions were prepared by dissolving vanillin at different
148 concentrations (1% and 3% w/v) in ethanol. Next, CS and vanillin solutions were mixed and the mixture
149 was stirred continuously at 50 °C for crosslinking reaction. ENR was loaded to the film preparation in
150 a concentration of 1%(w/v). Thereafter, PVA dissolved in distilled water (1% w/v) was poured into all
151 sample solutions to solidify the biopolymer films with the final ratio of PVA and CS at 1:2 (w/w).
152 Finally, the film solutions were poured into polytetrafluoroethylene Petri dishes (8×8cm) and
153 subsequently allowed to dry at room temperature for 24h. The peeled films obtained were stored in
154 airtight containers at room temperature before further testing. All the film preparation steps are
155 graphically presented in Figure 3.



156

157 **Figure 3.** The scheme of vanillin crosslinked CS-PVA film preparation with solvent-casting method

158 **2.3. Analytical Methods**

159 The surface structure of the polymer blend films was observed using a NANOSEM 450 (FEI, Hillsboro,
160 OR, USA) scanning electron microscope at 5.0 kV of accelerating voltage after sputter coated with
161 conductive gold/palladium layer.

162 The surface roughness and topology at nanometer scale of the drug loaded blend films were measured
163 with an AFM (Dimension Icon Bruker, Karlsruhe, Germany) in peak force tapping mode (noncontact
164 mode) using a ScanAsyst-Air Si/Nitride probe (Bruker, Santa Barbara, CA, USA) with $k = 0.4$ N/m of
165 spring constant value of the cantilever. Data were acquired on a scanning area of $5.0 \times 5.0 \mu\text{m}$ for each
166 sample with a scan rate of 1 Hz. Images were processed using the Gwyddion – Free SPM data analysis
167 software, version 2.55 (Czech Metrology Institute, Czech Republic) The height profiles and surface
168 roughness (S_a) were determined.

169 The appearance, thickness and mass uniformity were examined for visual evaluation of the polymer
170 films. The film thickness was measured at three random positions on the film by a digital micrometer
171 having a sensitivity of 0.001 mm. For the mass uniformity assessment, the films from casting plates
172 were cut into 2.5×2.5 cm square shapes (triplicate) and weighted by using a digital scaler.

173 The functional group identification in the blend films were examined by means of Fourier Transform
174 Infrared Spectroscopy (Nicolet iS5, Thermo Fisher, Waltham, USA). All ATR-FTIR spectra were
175 obtained at 64 scans at a resolution of 4 cm^{-1} over a wavenumber range of $4000\text{-}600 \text{ cm}^{-1}$. All the
176 readings performed at room temperature ($25 \pm 1^\circ\text{C}$). The processing of the spectra was achieved using
177 the Origin Pro program.

178 The elemental analysis of non-crosslinked and vanillin crosslinked CS-PVA blend films were
179 investigated with X-ray photoelectron spectroscopy (XPS) using the TFA XPS Physical Electronics
180 (Munich, Germany). Samples were placed on the sample holder and the base pressure in the analysis
181 chamber was set to 6×10^{-8} Pa. As the photoemission excitation, a monochromic Al $K\alpha_{1,2}$ X-ray source
182 (1486.6 eV) line was applied on the three different place on each sample with a $400\mu\text{m}$ spot size.
183 Photoelectrons were detected with a hemispherical analyzer, mounted at an angle of 45° and the energy
184 resolution was about 0.6 eV . Surface elemental concentrations were calculated from survey-scan spectra
185 which were aligned by setting the C1s peak at 285.0 eV , using the Multipak software version 9.6.0.

186 The distribution of ENR in blend films was studied by Laser Scanning Confocal Microscope (LSCM)
187 Olympus FLUOVIEW FV3000. Excitation wavelengths were 405 and 561 nm. The emission detection
188 window for the identification of ENR was set to 430-470 nm based on the data in the literature [44].
189 The objective with magnification 60x was used for analysis.

190

191 Thermal analysis was carried out using a TGA Q500 (TA Instruments, USA) thermogravimeter under
192 a nitrogen atmosphere with a flow of 50 mL min⁻¹. The temperature range of 25-600 °C was tested for
193 thermal stability at a heating rate of 10 °C min⁻¹. The Universal Analysis 2000 system was used for the
194 evaluation of the data.

195 The mechanical properties of the films were determined with a Testometric M350 tensile machine
196 (Testometric Company, Ltd. UK) according to the methodology described in Reference [44]. The films
197 were conditioned at room temperature, 50% relative humidity (RH) for 48 h and cut into strips
198 (80 mm×10 mm) prior to analysis. The test was performed at a crosshead speed of 5 mm/min with the
199 initial grip separation of 40mm. Five specimens were tested for each sample and the average value was
200 calculated. The tensile properties (Young's modulus, elongation at break, and tensile strength) were
201 evaluated by stress-strain curves.

202 The crosslinking degree of blend films was evaluated by ninhydrin assay [45] with quantitatively
203 determination of the ratio of consumed amino groups by reacting with vanillin to the free amino groups
204 in the non-crosslinked films. For the ninhydrin reagent preparation, Solution A (1.05 g citric acid, 0.4g
205 NaOH and 0.04 g SnCl₂·H₂O were dissolved in 25 mL deionized water) and Solution B (1 g ninhydrin
206 in 25 mL ethylene glycol monomethyl ether) were mixed and stirred for 45 min, then stored in the dark
207 bottle until further usage. The test samples were weighed and heated with 2 ml ninhydrin reagent at
208 100°C in a water bath for 30 min. After cooling down to room temperature, the solutions were diluted
209 with 1ml of 50% ethanol and subsequently the optical absorbance at 570 nm was recorded with an UV
210 spectrophotometer (Xylem Analytics Germany Sales GmbH & Co. KG, Weilheim, Germany). The
211 cross-linking degree of samples are calculated as follows:

$$212 \quad \text{Crosslinking degree (\%)} = \frac{C_o - C_v}{C_o} \times 100 \% \quad (1)$$

213 where C_o is the concentration of free amino groups in non-crosslinked samples and C_v is concentration
214 of free amino groups remaining in crosslinked samples. The experiment was repeated three times for
215 each sample and the result was expressed as an average value.

216 2.4. Swelling Measurement

217 The gravimetric method was performed to evaluate the swelling behavior of the blend films as a
218 function of the percentage of vanillin incorporated into the film formulations. For this, the films
219 (triplicate) without drug were dried to a constant weight and cut into 2.5 × 2.5 cm square shapes. Then
220 pre-weighed samples were immersed into a beaker containing 20 mL phosphate buffer solution (PBS)
221 (0.1 M, pH 7.4) and kept under constant slow stirring at room temperature for 24h. At each specified
222 time point, the films were taken from the solution and the excess surface water was removed gently by
223 blotting filter paper. Subsequently, the swollen films were weighed and the swelling degree was
224 calculated using equation [23]:

$$225 \quad \text{Swelling Degree (\%)} = \frac{W_s - W_i}{W_s} \times 100 \% \quad (2)$$

226 where (W_i) is the initial weight and (W_s) is the weight of the sample in the swollen state.

227 2.5. In-vitro Drug Release Test

228 The *in vitro* drug release study of ENR from non-crosslinked and vanillin crosslinked films was
229 conducted in PBS with pH 7.4 to mimic the *in vivo* environment. Briefly, the films with an area of 4cm²
230 were placed into 10 mL of PBS media and placed on an oscillating stirrer (100 rpm).

231 At the predetermined time intervals, aliquot samples (1 mL) were withdrawn and replaced with the
232 same volume of fresh media. After the samples appropriately diluted, the drug contents were
233 spectrophotometrically analysed by a Photolab 6600 UV-VIS photometer (Xylem Analytics Germany

234 Sales GmbH & Co. KG, Weilheim, Germany) at a wavelength of 285 nm for ENR. These studies were
235 performed in triplicates.

236 Besides, the desorption method was used to estimate the loading capacity of the films. For this, the
237 blend films were introduced in 2% (v/v) acetic acid for 3 days, subsequently the aliquots of the desorbed
238 solutions (1 mL) were withdrawn and their absorbance was measured by UV-VIS spectroscopy to
239 compare with the corresponding calibration curve ($\lambda = 285$ nm, Abs = 0.0814 ($\mu\text{g mL}^{-1}$); $R^2 = 0.9991$)


240 2.6. Statistical Analysis

241 For statistical comparison of data obtained from this study, one-way analysis of variance ANOVA was
242 employed using Microsoft Excel 2016, using ($P < 0.05$) as a significance level.

243 3. Results and Discussion

244 3.1. Surface Chemistry and Morphology

245 The appearance of the ENR loaded CS-PVA blend films is shown in Figure 4. As can be seen, the
246 orange logo on the background can be identified clearly through drug-loaded blend films which
247 confirms the formation of a homogeneous structure. The ENR loaded non-crosslinked film (Figure 4a)
248 is transparent without any color tone, but the vanillin crosslinked films show a yellowish tint, which is
249 attributed to the imine bond formation [46]. It is found that the films containing the low concentration
250 of vanillin have less opacity than those with a higher concentration, which is due to the difference in –
251 NH_2 –CHO molar ratios (1/1 and 1/3) corresponding to the Schiff bases.




252


253 **Figure 4.** Photographic images and SEM micrographs of (a,d) CS-ENR-PVA; (b,e) CS-1V-ENR-PVA; (c,f)
254 CS-3V-ENR-PVA

255 Figure 4 also shows the SEM micrographs of the surface of ENR-loaded CS-PVA based films with
 256 various concentrations of vanillin. As observed in SEM images, all samples show a plain and dense
 257 structure without pores. Furthermore, there can be seen some microcrystal form of ENR molecules
 258 randomly distributed over the CS-ENR-PVA non-crosslinked film surface (Figure 4d) which can
 259 probably be attributed to the low interactions between the drug and the polymer blends. With the vanillin
 260 addition, these microcrystal forms of drug molecules are significantly decreased on the CS-1V-ENR-
 261 PVA blend surface (Figure 4e). In case of increase in vanillin concentration from 1% to 3%, those
 262 structures become invisible and more uniform surface is observed on the CS-3V-ENR-PVA film
 263 micrograph. It is assumed that drug molecules bonded to CS-PVA matrix in the course of crosslinking
 264 reaction are not seen in the SEM micrographs due to the uniform distribution in polymer blend matrix.
 265 In order to confirm the presence of ENR and the interaction between drug and polymer substrates, FTIR
 266 spectrum and XPS were employed as tools for the measurement. It may be concluded from the SEM
 267 images that the crosslinking of the polymer blend with vanillin exerted the stabilizing effect of the
 268 polymer and minimized the risk of drug agglomeration [34,35]. To further understand the alterations
 269 on the drug loaded CS-PVA films AFM was performed.

270 Table 1 shows the average surface roughness values and cross section profiles of non-crosslinked and
 271 crosslinked drug loaded CS-PVA films. The blend film which has the highest surface roughness value
 272 of 17.9 is non-crosslinked CS-ENR-PVA. Moreover, irregular particles and macro-agglomerates which
 273 may belong to drug particles are observed on the topography image as is observed from the SEM image.
 274 However, with 1% vanillin incorporation to the films these cluster structures diminishes and surface
 275 roughness drastically reduces to 10.2 nm. Further increase in vanillin concentration up to 3% makes the
 276 film homogenous, smoother and these agglomerations become invisible. Similar results have been
 277 reported by various researchers in case of other chitosan crosslinking based films and membranes
 278 [47,48].

279 **Table 1.** Average roughness values and AFM images of drug loaded CS-PVA blends





280

281 For uniform distribution of drug molecules, weight and thickness parameters are the key variables that
 282 control the sustained delivery [49]. The thickness of the films was found to be in the range of $7.2 \pm$
 283 $0.4 \mu\text{m}$ to $16.7 \pm 1.9 \mu\text{m}$ and the weight of the films ($2 \times 2 \text{ cm}^2$) were between $7.0 \pm 0.3 \text{ mg}$ to
 284 $10.6 \pm 2.4 \text{ mg}$ (Table 2). Transdermal films of ENR were found to have uniform thickness and weight
 285 which ensured homogeneity.


286

Table 2. Values for thickness, weight and the swelling index for the prepared films

Sample type	Thickness (μm)	Weight (mg)	Swelling Degree (%)
CS	14.0 ± 0.7	7.0 ± 0.3	319.3
CS-PVA	7.2 ± 0.4	7.0 ± 1.4	243.7
CS-1V-PVA	10.8 ± 0.8	7.3 ± 1.5	43.3
CS-3V-PVA	16.7 ± 1.9	10.6 ± 2.4	36.3

289

290 The distribution of ENR in polymer blends was studied by LSCM. The typical emission wavelength for
 291 ENR is in the range of 450-455 nm [44]. As shown in Figure 5, CS-PVA blend film without ENR gives
 292 no fluorescence signal in the range of 430-470 nm. For samples with ENR, fluorescence signals are
 293 obtained in the blue to cyan colored images. However, the emission intensity of blue color decreases
 294 with the increase of vanillin content. In the drug loaded non-crosslinked sample, the surface is emitting
 295 blue without discontinues. This could be attributed to the abundance of microcrystal form of ENR
 296 molecules on the film surface, as can be seen in SEM images (Fig 4-d). With the vanillin incorporation,
 297 obtained fluorescence signal is decreased and CS-3V-ENR-PVA films exhibits a considerably reduced
 298 cyan emission. This might be result of the minimized risk of drug agglomeration on the surface and
 299 restricted the molecular mobility of the drug molecules in the hybrid network structure as demonstrated
 300 in Figure 2. The XPS results and drug loading tests shows that the highest drug amount detected on CS-
 301 3V-ENR-PVA films. In contrast to these results, a reduce in the emission intensity of ENR molecules
 302 might be explained by aggregation-induced emission enhancement theory in which the
 303 photoluminescence efficiency of luminophores increase by aggregation [51]. To gain further insight
 304 into ENR photophysical property, further investigation is needed.



305

306 **Figure 5.** Laser Scanning Confocal Microscope (LSCM) comparison of polymer films at fluorescence signal in
 307 the range 430-470 nm

308 The ATR-FTIR spectra of CS-PVA blends with different vanillin content and with/without ENR loaded
 309 films are presented in Figure 6. The FTIR spectrum of CS-PVA blend film reveals the characteristic
 310 peaks of both CS and PVA (Figure 6a). The –OH stretching of PVA and –NH stretching of CS are
 311 overlapped and appeared as a broad band between 3355 cm^{-1} and 3286 cm^{-1} . The asymmetric and
 312 symmetric –CH stretching of –CH₂ groups of PVA and CS are observed at 2923 cm^{-1} and 2854 cm^{-1} ,
 313 respectively. The peak at 1727 cm^{-1} is attributed to the C=O bond stretching of PVA from the remaining
 314 acetate groups during the production of PVA from polyvinyl acetate [52]. The N–H bending in amino
 315 (–NH₂) groups and O–H bending in hydroxyl groups of CS are clearly identified at 1550 cm^{-1} and 1411
 316 cm^{-1} , respectively [53]. The C–H vibrations in the ring are identified as a peak at 1326 cm^{-1} for CS. The
 317 peak at 1257 cm^{-1} corresponds to the C–O stretching for PVA. The characteristic C–O–C vibrations in
 318 rings of CS are observed as sharp peaks at 1072 cm^{-1} and 1033 cm^{-1} [54].




Figure 6. FTIR spectra of (a) without drug loading CS-PVA blends; (b) ENR loaded CS-PVA blends with different vanillin content

The FTIR spectra of crosslinked CS-PVA blends with 1% and 3% vanillin exhibited the major peaks associated with CS and PVA components. For 1% vanillin crosslinked blend film (CS-1V-PVA) exhibited some differences from the non-crosslinked one. The OH band at 3324 cm^{-1} shifted to the 3360 cm^{-1} that indicating the generation of the hydrogen bonding between CS and vanillin [37]. The peak at 1645 cm^{-1} can be seen clearly due to the stretching vibration of the C=N bond that confirms the crosslinking reaction between the NH_2 group of CS and the HC=O group of vanillin [55]. Besides, the C-C stretching of vanillin ring can be identified at 1593 cm^{-1} and 1516 cm^{-1} . The peak at 1275 cm^{-1} shows the ether groups ($-\text{C-OCH}_3$) in vanillin [56]. The FTIR spectrum of CS-PVA blend showed the vanillin related peaks more distinguished when the three times higher vanillin content was used (CS-3V-PVA). The peak intensities at 1589 cm^{-1} and 1519 cm^{-1} of the benzene ring of vanillin increased significantly. The vanillin rings out of plane bending vibrations become clear at 732 cm^{-1} [57]. The three times increment of the vanillin content did not change the OH band related to the hydrogen bonding.

ENR originated FTIR absorptions can be clearly identified in the spectrum of ENR loaded CS-PVA blends (Figure 6b). The sharp peak at 1734 cm^{-1} is due to the C=O vibration of both ENR and PVA. Also, the C=O stretching absorption peak of ENR ring is observed at 1625 cm^{-1} [53]. The C=C stretching vibrations of the aromatic ring and C-F bonds of ENR are appeared at 1465 cm^{-1} and 1259 cm^{-1} , respectively [58]. The increased vanillin content in the formulation was also confirmed by the FTIR analysis. The typical C=C stretching of the vanillin ring and out of plane bending vibrations of vanillin ring at 1589 cm^{-1} and 738 cm^{-1} can be identified respectively. Moreover, the spectrum of 3% vanillin crosslinked ENR loaded film also confirmed that there is an interaction between the ENR and CS-PVA blends. After the drug loading, the shifting of the peaks of $-\text{OH}$ stretching and carbonyl peaks became clear and this drug-matrix interaction might be due to the polar functional groups in ENR [59].


The quantitative atomic compositions of the CS-PVA blend films was determined by XPS measurements. The elemental content of carbon, oxygen, nitrogen, and fluorine in each sample is shown in Table 3. According to the chemical structure of CS and PVA, the XPS analysis of the blend films

347 without drug content indicates that the surface is dominated by carbon and oxygen species. Small
 348 amounts of nitrogen were also detected which assigned to CS backbone.

349 **Table 3.** The atomic weight percentage of CS-PVA blend films

Sample type	Composition (%)				Ratio O/C
	C	N	O	F	
350 CS-PVA	71.7	5.1	23.2	-	0.32
351 CS-1V-PVA	72.4	4.1	23.5	-	0.33
CS-3V-PVA	71.1	4.1	24.8	-	0.35
352 CS-ENR-PVA	67.5	6.4	25.4	0.6	0.38
CS-1V-ENR-PVA	72.8	5.6	20.9	0.8	0.29
353 CS-3V-ENR-PVA	74.4	2.9	21.6	1.1	0.29

354 As it is shown in Table 3, antibiotic drug-loaded films display fluorine concentrations between 0.6-
 355 1.1% due to the incorporation of the ENR. In accordance with the structure of ENR that contains only
 356 one fluorine atom, these low concentrations were expected. Nitrogen is present as well in ENR,
 357 however, its concentration is lower than in CS. The concentration of nitrogen decreases from 6.4% to
 358 2.9%, while fluorine shows the opposite trend by increasing the vanillin content. The presence of
 359 fluorine (C-F bond) can be also observed in carbon spectrum as a new peak at about ~289 eV (Figure
 360 7), which allows determining the highest drug content of the films. The highest drug amount detected
 361 on CS-3V-ENR-PVA films may be due to the increased crosslinking degree introduced by vanillin
 362 addition, leading to more widespread immobilization of the drug. When the results are evaluated
 363 together with the SEM images given in Figure 4, it is seen that vanillin leads to an improvement in the
 364 stabilizing effect of the polymer which results in better interactions with drug molecules.




365

366 **Figure 7.** High-resolution XPS spectra of carbon C1s peak.

367 The thermal behavior of the raw films (CS, PVA) and the blends with different vanillin concentration
 368 was investigated by TGA-DTG analysis (Figure 8). It can be seen from the TGA curves all films show
 369 weight loss in a range of 4-11% at 30-130 °C due to the moisture and volatile compounds evolution.
 370 CS film shows the thermal degradation at 295 °C whereas PVA film thermogram exhibits two onsets
 371 regarding its hydroxyl side groups degradation at 316 °C and polyene backbone degradation at 447 °C
 372 [60] (Figure 8a). The TGA trend recorded for the CS-PVA blend is similar to those of raw CS and PVA
 373 films. However, TGA curves of CS film shift toward high temperature (to 301 °C) along with the PVA
 374 content, which confirms an increase in the thermal stability of the blend film regarding only CS film.
 375 Also, the DTG peak for CS-PVA blend at the 162 °C (Figure 8b) accounts for acetic acid and water
 376 interaction with polar domains [61] which led to a broad and shifted peak. On the other hand, the
 377 addition of vanillin slightly decreases the thermal stability of the CS-PVA matrix to 291 °C when the
 378 amount of vanillin is equal or higher than 1 wt.% (Figure 8d). In accordance with this finding, Abraham

379 et al. [21] and Kasai et al. [33] studied the effects of vanillin and PVA on thermal properties of CS films
 380 and found that thermal stability of CS matrix with PVA slightly decreased by vanillin content. However,
 381 the obtained higher initial decomposition temperature (290 °C) confirms that the drug-loaded polymer
 382 blends with vanillin are highly thermally stable.




383
 384 **Figure 8.** TGA (a,c) and DTG (b,d) curves for CS, PVA, and blend films with different vanillin content.

385 The mechanical performance of CS-PVA blend films and the effects of vanillin content were
 386 investigated based on tensile strength (TS), elongation at break (EB), and young modulus (YM). As it
 387 is shown in Table 4, CS-PVA films exhibit the lowest TS and YM values, and with the addition of
 388 vanillin, the mechanical properties of CS-1V-PVA films increased by 18.9%. However, EB of vanillin
 389 crosslinked films slightly decreased from 1.65% to 1.53% when compared to non-crosslinked films. By
 390 further increasing the vanillin content in the blend matrix, TS continue to rise and YM has reached to a
 391 maximum value of 5.16 GPa, meanwhile EB decreases to a lowest value of 1.47%. These improvements
 392 may ascribe to the crosslinking reaction between functional groups of CS and vanillin in which the
 393 mobility of polymer chains is restricted and thereby the rigidity is augmented [62,63]. In the literature,
 394 it is stated that increasing amount of crosslinking agents leads promoted TS and decreased EB of
 395 biopolymer films [63]. A similar study on ethyl vanillin crosslinked CS-PVA based composite films
 396 prepared by Narasagoudr et al. [64] reported an almost 2-fold increase in TS, and in other study Zhang
 397 et al. [26] stated that vanillin incorporation led to a 1.53 fold increment in the mechanical properties.

398 **Table 4.** Tensile strength, elongation at break and young modulus of the polymer films

Sample type	Tensile Strength (MPa)	Elongation at Break (%)	Young Modulus (GPa)
CS-PVA	49.72 ± 12.01	1.65 ± 1.45	3.88 ± 0.09
CS-1V-PVA	59.12 ± 3.98	1.53 ± 0.14	4.29 ± 0.24
CS-3V-PVA	63.8 ± 8.76	1.47 ± 0.49	5.16 ± 0.55

399 Ninhydrin assay is an indirect method for quantification of the remaining free amino groups and
 400 calculation of the crosslinking degree in the blended films. The reaction between the free amino groups
 401 of CS and ninhydrin reagent forms chitosan-ninhydrin complexes which have a purple color known as
 402 Ruhemann's purple and a decrease in the ninhydrin chromophore is directly related to the extent of
 403 crosslinking. As seen in Figure 9, the color lightens with the increase in vanillin concentration which
 404 indicates a decrease in the number of free amino groups. The crosslinking degree of CS-PVA blend
 405 films is $26.3 \pm 3.25\%$. This result could be attributed to the formation intermolecular hydrogen bonds
 406 between amino and hydroxyl groups of CS and hydroxyl groups of PVA [65,66]. The highest degree of
 407 crosslinking is achieved when the amount of vanillin is 3 % ($74.4 \pm 2.5\%$), confirming the Schiff base
 408 reaction between amino groups of CS and aldehyde group of vanillin. In case of CS-1V-PVA films,
 409 the decrease in the vanillin concentration slightly decreases the crosslinking degree to $69.3 \pm 2.9\%$. The
 410 crosslinking degrees obtained in the present work are similar to those reported. Abraham et al. [21]
 411 synthesized microwave assisted crosslinked CS with 66% crosslinking degree for 1% vanillin
 412 concentration and Jagadish et al [67] reported a 63% crosslinking for vanillin modified CS with sodium
 413 cyanoborohydride reduction.



414
 415 **Figure 9.** Crosslinking degree of CS-PVA films and the color of the sample–ninhydrin complex (inset image)

416 *3.2. Swelling Measurement*


417 In transdermal systems, the capacity of swelling plays a significant role for loading and release behavior
 418 of the drug [68]. An optimum degree of swelling is necessary since the low swelling forms a weak
 419 bioadhesive strength whereas high swelling causes a burst drug release that affects the delivery
 420 efficiency [69]. The obtaining of this optimum level of swelling is directly related to the type of
 421 polymers incorporated in the blend as well as the crosslinking agents.

422 Table 2 shows the degree of swelling for the raw CS film and all the blend except drug-loaded
 423 counterparts. All preparations show a swelling degree that ranges from 319.3% to 36.3% with
 424 significant difference ($p < 0.05$). The highest swelling capacity is exhibited by the raw CS film which
 425 has hydrophilic groups on the polymer backbone to form hydrogen bonds with water. The swelling
 426 degree obtained for CS-PVA blend is 243.7% which is distinctly lower than the obtained for raw CS
 427 film. This reduction in swelling volume could be attributed to the decrease in the number of hydrophilic
 428 groups in the blend due to the interactions between the functional groups of CS and PVA [70]. It can
 429 be also concluded from the table that varying vanillin concentration has a strong influence on the

430 swelling capacity by decreasing it from 243.7% to 36.3%. As the material crosslinked with vanillin, the
431 CS-PVA matrix interactions increase and a more rigid network forms by the inter and intra-polymer
432 reactions; hence the water penetration into polymer blend structure is restricted by these new
433 interactions. As expected, equilibrium water contents of the vanillin crosslinked films exhibit a
434 decreasing tendency with increasing vanillin content due to CS amine groups being more reactive to
435 vanillin than to hydroxyls of PVA. This result is in agreement with previous studies [71,72] which
436 reported that crosslinker decreases the swelling degree due to acetylation and the formation of the Schiff
437 base [73] between the CS and vanillin molecules that restricts the penetration of water molecules.
438 According to reported literature, such moderate percent swelling is regarded as sufficient for proper
439 adhesion and *in vitro* drug release [74].

440 3.4. *In-vitro* Drug Release Test

441 The *in vitro* release profiles of ENR from CS-PVA films are presented in Figure 10, in terms of
442 cumulative release versus time. In the release profiles, two-step process based on a slight initial burst
443 release and following subsequent slower release is beneficial as it helps to achieve the therapeutic drug
444 concentration for blocking of biofilm formation in the first place and then maintaining a sustained and
445 controlled release [37]. In the initial burst release phase, ENR molecules absorbed and entrapped near
446 the surface were released due to the high dissolution rate of the polymer near the surface. For the non-
447 crosslinked CS-PVA blend, the ENR was rapidly released and its cumulative release reached to 50% in
448 3h. However, the release rate was significantly reduced to 15-25% by the crosslinking reaction of CS
449 with vanillin. The subsequent slower release from vanillin crosslinked films accounted for the effect of
450 vanillin on limiting access of water and dissolution of the drug. Figure 10 showed that with the increase
451 in vanillin content, the 3% vanillin crosslinked film yielded the lowest cumulative percentages of drug
452 release in 12h. Besides the crosslinking, this can be also explained by the hydrophobicity of the drug
453 delivery system which also has impact on controlling the release. Here, the hydrophobic interactions of
454 vanillin crosslinked blend films were increased with the vanillin concentration and led to a retarded
455 release of drug from the polymer matrix [75,76].



456

457

Figure 10. *In-vitro* drug release profiles of ENR-loaded CS-PVA films

458 The calculated drug loading efficiency of the non-crosslinked film in the PBS medium was rather lower
459 than those vanillin crosslinked ones (Table 5). The ENR content for 3% vanillin crosslinked film was
460 found the highest of drug content with 94.8%, which is also coincided with XPS results. When the
461 vanillin concentration decreases from 3% to 1%, the ENR loading also decreases significantly to 59.9%.
462 This drug loading behavior is attributed to the higher crosslinker concentration which mediates the
463 higher Schiff Base reaction between the amino groups of CS and aldehyde group of vanillin that

464 increase the retention of drug molecules. In comparison, the release rate of ENR followed the
465 descending order: CS-ENR-PVA > CS-1V-ENR-PVA > CS-3V-ENR-PVA.

466 **Table 5.** Effect of vanillin concentration on the release kinetics

Formulation	Drug Loading Efficiency (%)	Zero order	First order	Higuchi	Korsmeyer-Peppas	
		R ²	R ²	R ²	R ²	n
CS-ENR-PVA	49.1	0.924	0.960	0.982	0.898	0.63
CS-1V-ENR-PVA	59.9	0.896	0.922	0.984	0.943	0.52
CS-3V-ENR-PVA	94.8	0.832	0.851	0.964	0.977	0.41

467
468 The mechanism of drug release for studied formulations was investigated using various kinetic models
469 and the results were presented in Table 5. The best fit for the highest value of the regression coefficient
470 (R^2) provides the release model. The regression coefficient value for all the ENR-loaded films is found
471 to be the highest for the Higuchi model which implies that the release mechanism is controlled by
472 diffusion and erosion (dissolution) forces. Once the mechanism follows the Higuchi model, further
473 confirmation of the release profile is investigated by the Korsmeyer-Peppas model to explain the
474 diffusion type from the polymer matrix [77]. In this model, the diffusion mechanism from the polymer
475 matrix is commanded by the exponent value 'n'. This value indicates that the diffusion mechanism is
476 Fickian, anomalous transport, or super case II transport [78]. Herein, the 'n' values decrease with the
477 increase in vanillin concentration. The mechanism for the non-crosslinked and 1% vanillin crosslinked
478 film was governed anomalous transport ($0.45 < n < 0.89$) which indicates that the release tends to be
479 controlled by swelling and polymer relaxation. This result also coincides with the swelling degrees of
480 these two films which have higher swelling values than the 3% vanillin crosslinked film. The value of
481 $n \leq 0.45$ for 3% vanillin crosslinked film suggested that the drug release mechanism closely fitted
482 Fickian diffusion which also showed that this approach helped reduce the initial burst release.
483 Furthermore, the reduced release rate of the ENR from the 3% vanillin crosslinked film correlated to
484 its lower swelling degree as reported in previous studies. [69,79].

485 **4. Conclusions**

486 The matrix-type transdermal film systems based on CS and PVA were successfully prepared through a
487 simple and easily reproducible solvent-casting method without using any penetration enhancer and
488 plasticizer. The only addition to the polymer blend was vanillin as a crosslinker that was chosen for its
489 natural origin. The vanillin crosslinked film formation was confirmed by FTIR and ninhydrin assay.
490 The survey scan XPS spectra demonstrated that the increase in the vanillin concentration resulted in
491 increased drug loading efficiency. Furthermore, SEM images showed that the presence of vanillin
492 reduced the risk of drug agglomeration and provided uniform distribution of the ENR in the blend films.
493 To verify this phenomenon, the topography of films with/without vanillin was investigated by AFM
494 analysis and the images demonstrated that the surface roughness of vanillin incorporated film is lower
495 as a result of crosslinking. The investigations on the mechanical properties indicated that tensile
496 properties were increased considerably by vanillin addition, the film being stiffer than non-crosslinked
497 films. The optimum swelling degree of the prepared films mainly originated from the vanillin presence
498 that led to the construction of the Schiff-base bond. As a result, the restricted movement of polymer
499 molecule chains in a compact network presented a sustained drug release behavior. It was found that
500 ENR release was influenced by the amount of vanillin incorporated within the CS-PVA blend,
501 especially, adding amount 3%. These findings will pave the way for a future study to characterize
502 important parameters, such as pH, concentration and temperature and also for *in vivo* studies. Overall,
503 all these results suggest that the proposed material with higher crosslink density can be used as an ideal
504 matrix with enhanced release kinetics for potential local drug delivery applications.

505 **Acknowledgements:** Authors thank the Internal Grant Agency of Tomas Bata University in Zlín
506 (IGA/CPS/2021/001), the Ministry of Education, Youth, and Sports of the Czech Republic (project no.
507 LTACH17015) and NPU Program I (LO1504) for financial support.

508 **Conflicts of Interest:** The authors declare no conflict of interest.

509 **References**

- 510 1. Sachan, R., Bajpai, M. Transdermal drug delivery system: A Review. *Int. J. Res. Dev. Pharm.*
511 *L. Sci.*, **2013**, 3(1), pp. 748-765. doi: 10.21276/IJRDP
- 512 2. Marwah, H., Garg, T., Goyal, A. K., Rath, G. Permeation enhancer strategies in transdermal
513 drug delivery. *Drug Delivery*, **2014**, 23(2), 564–578. doi: 10.3109/10717544.2014.935532
- 514 3. Mehtani, D., Seth, A., Sharma, P., Maheshwari, N., Kapoor, D., Shrivastava, S. K., Tekade, R.
515 K. Biomaterials for Sustained and Controlled Delivery of Small Drug Molecules. *Biomaterials*
516 *and Bionanotechnology*, **2019**, 89-152. doi:10.1016/b978-0-12-814427-5.00004-4
- 517 4. Saikia, C., Gogoi, P. Chitosan: A Promising Biopolymer in Drug Delivery Applications.
518 *Journal of Molecular and Genetic Medicine*, **2015**, S4. doi:10.4172/1747-0862.s4-006
- 519 5. Bayat, M., Nasri, S. Injectable microgel–hydrogel composites “plum pudding gels”: New
520 system for prolonged drug delivery. *Nanomaterials for Drug Delivery and Therapy*, **2019**, 343-
521 372. doi:10.1016/b978-0-12-816505-8.00001-1
- 522 6. Karkossa, F., Klein, S. Individualized in vitro and in silico methods for predicting in vivo
523 performance of enteric-coated tablets containing a narrow therapeutic index drug. *European*
524 *Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 135, 13-24
525 doi:10.1016/j.ejpb.2018.12.004
- 526 7. Siddaramaiah, K. P., Divya K. H., Mhemavathi B. T., Manjula D. S. Chitosan/HPMC Polymer
527 Blends for Developing Transdermal Drug Delivery Systems. *Journal of Macromolecular*
528 *Science*, **2006**, Part A: Pure and Applied Chemistry, 43(3), 601-607.
529 doi:10.1080/10601320600575231
- 530 8. Basavaraj, K. H., Johnsy, G., Navya, M. N., Rashmi, R., Siddaramaiah. Biopolymers as
531 Transdermal Drug Delivery Systems in Dermatology Therapy. *Critical Reviews in Therapeutic*
532 *Drug Carrier Systems*, **2010**, vol. 27, no. 2, pp. 155–185.
533 doi:10.1615/critrevtherdrugcarriersyst.v27.i2.20.
- 534 9. Arriagada, F., Morales, J. Limitations and Opportunities in Topical Drug Delivery: Interaction
535 Between Silica Nanoparticles and Skin Barrier. *Current Pharmaceutical Design*, **2019**, 25(4),
536 455-466. doi:10.2174/1381612825666190404121507
- 537 10. Shaker, D. S., Ishak, R. A., Ghoneim, A., Elhuoni, M. A. Nanoemulsion: A Review on
538 Mechanisms for the Transdermal Delivery of Hydrophobic and Hydrophilic Drugs. *Scientia*
539 *Pharmaceutica*, **2019**, 87(3), 17. doi:10.3390/scipharm87030017
- 540 11. Muzzalupo, R., Tavano, L. Niosomal drug delivery for transdermal targeting: Recent advances.
541 *Research and Reports in Transdermal Drug Delivery*, **2015**, 23. doi:10.2147/rrtd.s64773
- 542 12. Liu, H., Wang, C., Li, C., Qin, Y., Wang, Z., Yang, F., Wang, J., et al. A functional chitosan-
543 based hydrogel as a wound dressing and drug delivery system in the treatment of wound
544 healing. *RSC Advances*, **2018**, 8(14), 7533–7549. doi: 10.1039/c7ra13510f
- 545 13. Nawaz, A., Khan, N., Vigneswaran, T. Chitosan and Its Roles in Transdermal Drug Delivery.
546 *Handbook of Sustainable Polymers*, **2015**, 557–586. doi: 10.1201/b19600-17
- 547 14. Barclay, T. G., Day, C. M., Petrovsky, N., Garg, S. Review of polysaccharide particle-based
548 functional drug delivery. *Carbohydrate Polymers*, **2019**, 221, 94-112.
549 doi:10.1016/j.carbpol.2019.05.067
- 550 15. Gao, H.-X., He, Z., Sun, Q., He, Q., Zeng, W.C. A functional polysaccharide film forming by
551 pectin, chitosan, and tea polyphenols. *Carbohydrate Polymers*, **2019**, 215, 1–7. doi:
552 10.1016/j.carbpol.2019.03.029
- 553 16. Ozaltin, K., Postnikov, P. S., Trusova, M. E., Sedlarik, V., & Martino, A. D. Polysaccharides
554 based microspheres for multiple encapsulations and simultaneous release of proteases.
555 *International Journal of Biological Macromolecules*, **2019**, 132, 24–31. doi:
556 10.1016/j.ijbiomac.2019.03.189
- 557 17. Long, J., Etxeberria, A. E., Nand, A. V., Bunt, C. R., Ray, S., Seyfoddin, A. (2019). A 3D
558 printed chitosan-pectin hydrogel wound dressing for lidocaine hydrochloride delivery.
559 *Materials Science and Engineering: C*, 104, 109873. doi: 10.1016/j.msec.2019.109873

- 560 18. Govindaraj, P., Abathodharanan, N., Ravishankar, K., Raghavachari, D. Facile preparation of
561 biocompatible macroporous chitosan hydrogel by hydrothermal reaction of a mixture of
562 chitosan-succinic acid-urea. *Materials Science and Engineering: C*, **2019**, 104, 109845. doi:
563 10.1016/j.msec.2019.109845
- 564 19. Bellich, B., D'Agostino, I., Semeraro, S., Gamini, A., Cesàro, A. "The Good, the Bad and the
565 Ugly" of Chitosans. *Marine Drugs*, **2016**, 14(5), 99. doi: 10.3390/md14050099
- 566 20. He, W., Guo, X., Xiao, L., Feng, M. Study on the mechanisms of chitosan and its derivatives
567 used as transdermal penetration enhancers. *International Journal of Pharmaceutics*, **2009**,
568 382(1-2), 234-243. doi:10.1016/j.ijpharm.2009.07.038
- 569 21. Abraham, S., Rajamanick, D., Srinivasan, B. Preparation, Characterization and Cross-linking
570 of Chitosan by Microwave Assisted Synthesis. *Science International*, **2018**, 6(1), 18–30. doi:
571 10.17311/sciintl.2018.18.30
- 572 22. Walke, S., Srivastava, G., Nikalje, M., Doshi, J., Kumar, R., Ravetkar, S., Doshi, P. Fabrication
573 of chitosan microspheres using vanillin/TPP dual crosslinkers for protein antigens
574 encapsulation. *Carbohydrate Polymers*, **2015**, 128, 188–198.
575 doi:10.1016/j.carbpol.2015.04.020
- 576 23. Wang, L., Guo, H., Wang, J., Jiang, G., Du, F., Liu, X. Effects of Herba Lophatheri extract on
577 the physicochemical properties and biological activities of the chitosan film. *International*
578 *Journal of Biological Macromolecules*, **2019**, 133, 51–57. doi: 10.1016/j.ijbiomac.2019.04.067
- 579 24. Chen, C., Liu, L., Huang, T., Wang, Q., Fang, Y. E. Bubble template fabrication of
580 chitosan/poly(vinyl alcohol) sponges for wound dressing applications. *International Journal of*
581 *Biological Macromolecules*, **2013**, 62, 188–193. doi: 10.1016/j.ijbiomac.2013.08.042
- 582 25. Bhumkar, D. R., Pokharkar, V. B. Studies on effect of pH on cross-linking of chitosan with
583 sodium tripolyphosphate: A technical note. *AAPS PharmSciTech*, **2006**, 7(2). doi:
584 10.1208/pt070250
- 585 26. Zhang, Z.-H., Han, Z., Zeng, X.-A., Xiong, X.-Y., Liu, Y.-J. Enhancing mechanical properties
586 of chitosan films via modification with vanillin. *International Journal of Biological*
587 *Macromolecules*, **2015**, 81, 638–643. doi: 10.1016/j.ijbiomac.2015.08.042
- 588 27. Zhou, G., A., R., Ge, H., Wang, L., Liu, M., Wang, B., Fan, Y., et al. Research on a novel poly
589 (vinyl alcohol)/lysine/vanillin wound dressing: Biocompatibility, bioactivity and antimicrobial
590 activity. *Burns*, **2014**, 40(8), 1668–1678. doi: 10.1016/j.burns.2014.04.005
- 591 28. Jimtaisong, A., & Saewan, N. Plant-Derived Polyphenols as Potential Cross-Linking
592 Agents for Methylcellulose-Chitosan Biocomposites. *Solid State Phenomena*, **2018**, 283, 140-
593 146. doi:10.4028/www.scientific.net/ssp.283.140
- 594 29. Dalmolin, L. F., Khalil, N. M., Mainardes, R. M. Delivery of vanillin by poly(lactic-acid)
595 nanoparticles: Development, characterization and in vitro evaluation of antioxidant activity.
596 *Materials Science and Engineering: C*, **2016**, 62, 1–8. doi: 10.1016/j.msec.2016.01.031
- 597 30. Kamaraj, S., Palanisamy, U. M., Mohamed, M. S. B. K., Gangasalam, A., Maria, G. A.,
598 Kandasamy, R. Curcumin drug delivery by vanillin-chitosan coated with calcium ferrite hybrid
599 nanoparticles as carrier. *European Journal of Pharmaceutical Sciences*, **2018**, 116, 48–60. doi:
600 10.1016/j.ejps.2018.01.023
- 601 31. Xu, C., Zhan, W., Tang, X., Mo, F., Fu, L., Lin, B. Self-healing chitosan/vanillin hydrogels
602 based on Schiff-base bond/hydrogen bond hybrid linkages. *Polymer Testing*, **2018**, 66, 155–
603 163. doi: 10.1016/j.polymertesting.2018.01.016
- 604 32. Zou, Q., Li, J., Li, Y. Preparation and characterization of vanillin-crosslinked chitosan
605 therapeutic bioactive microcarriers. *International Journal of Biological Macromolecules*, **2015**,
606 79, 736–747. doi: 10.1016/j.ijbiomac.2015.05.037
- 607 33. Kasai, D., Chougale, R., Masti, S., Narasgoudar, S. Thermal degradation of ternary blend films
608 containing PVA/chitosan/vanillin. **2018** doi: 10.1063/1.5032561
- 609 34. Baghel, S., Cathcart, H., Oreilly, N. J. ChemInform Abstract: Polymeric Amorphous Solid
610 Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State
611 Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System
612 Class II Drugs. *ChemInform*, **2016**, 47(42). doi: 10.1002/chin.201642262

- 613 35. Sahoo, A., Kumar, N. K., Suryanarayanan, R. Crosslinking: An avenue to develop stable
614 amorphous solid dispersion with high drug loading and tailored physical stability. *Journal of*
615 *Controlled Release*, **2019**, 311-312, 212–224. doi: 10.1016/j.jconrel.2019.09.007
- 616 36. Wang, H., Qian, J., Ding, F. Emerging Chitosan-Based Films for Food Packaging Applications.
617 *Journal of Agricultural and Food Chemistry*, **2018**, 66 (2), 395-413 doi:
618 10.1021/acs.jafc.7b04528
- 619 37. Peng, H., Xiong, H., Li, J., Xie, M., Liu, Y., Bai, C., Chen, L. Vanillin cross-linked chitosan
620 microspheres for controlled release of resveratrol. *Food Chemistry*, **2010**, 121(1), 23–28. doi:
621 10.1016/j.foodchem.2009.11.085
- 622 38. Li, P.-W., Wang, G., Yang, Z.-M., Duan, W., Peng, Z., Kong, L.-X., Wang, Q.-H.
623 Development of drug-loaded chitosan–vanillin nanoparticles and its cytotoxicity against HT-
624 29 cells. *Drug Delivery*, **2014**, 23(1), 30–35. doi: 10.3109/10717544.2014.900590
- 625 39. Sangalli, M., Zema, L., Maroni, A., Foppoli, A., Giordano, F., Gazzaniga, A. Influence of
626 betacyclodextrin on the release of poorly soluble drugs from inert and hydrophilic
627 heterogeneous polymeric matrices. *Biomaterials*, **2001**, 22(19), 2647-2651. doi:10.1016/s0142-
628 9612(01)00005-9
- 629 40. Parikh, T., Gupta, S. S., Meena, A. K., Vitez, I., Mahajan, N., Serajuddin, A. T. Application of
630 Film-Casting Technique to Investigate Drug–Polymer Miscibility in Solid Dispersion and Hot-
631 Melt Extrudate. *Journal of Pharmaceutical Sciences*, **2015**, 104(7), 2142-2152.
632 doi:10.1002/jps.24446
- 633 41. Qian, F., Huang, J., Hussain, M. A. Drug–Polymer Solubility and Miscibility: Stability
634 Consideration and Practical Challenges in Amorphous Solid Dispersion Development. *Journal*
635 *of Pharmaceutical Sciences*, **2010**, 99(7), 2941-2947. doi:10.1002/jps.22074
- 636 42. Zhang, X., Xing, H., Zhao, Y., Ma, Z. Pharmaceutical Dispersion Techniques for Dissolution
637 and Bioavailability Enhancement of Poorly Water-Soluble Drugs. *Pharmaceutics*, **2018**, 10(3),
638 74. doi:10.3390/pharmaceutics10030074
- 639 43. Shi, X., Huang, W., Xu, T., Fan, B., Sheng, X. Investigation of Drug–Polymer Miscibility and
640 Solubilization on Meloxicam Binary Solid Dispersion. *Journal of Pharmaceutical Innovation*,
641 2019, 15(1), 125-137. doi:10.1007/s12247-019-09378-4
- 642 44. Ma, L. The investigation of Fluorescence spectra and Fluorescence quantum yield of
643 Enrofloxacin. *Journal of Chemical, Environmental and Biological Engineering*, **2018**, 2(1), 11.
644 doi:10.11648/j.jcebe.20180201.13
- 645 45. Vargun, E., Ozaltin, K., Fei, H., Harea, E., Vilčáková, J., Kazantseva, N., Saha, P.
646 Biodegradable porous polylactic acid film as a separator for supercapacitors. *Journal of Applied*
647 *Polymer Science*, **2020**, 137(42), 49270. doi:10.1002/app.49270
- 648 46. Cui, L., Jia, J., Guo, Y., Liu, Y., & Zhu, P. Preparation and characterization of Ipn Hydrogels
649 composed of chitosan and Gelatin Cross-linked by Genipin. *Carbohydrate Polymers*, **2014**, 99,
650 31-38. doi:10.1016/j.carbpol.2013.08.048
- 651 47. Marin, L., Stoica, I., Mares, M., Dinu, V., Simionescu, B. C., Barboiu, M. Antifungal vanillin–
652 imino-chitosan biodynameric films. *Journal of Materials Chemistry B*, **2013**, 1(27), 3353. doi:
653 10.1039/c3tb20558d
- 654 48. Aryaei, A., Jayatissa, A. H., Jayasuriya, A.C. Nano and micro mechanical properties of uncross-
655 linked and cross-linked chitosan films. *Journal of the Mechanical Behavior of Biomedical*
656 *Materials*, **2012**, 5(1), 82-89. doi:10.1016/j.jmbbm.2011.08.006
- 657 49. Karakeçili, A. G., Satriano, C., Gümüşderelioğlu, M., Marletta, G. Surface characteristics of
658 ionically crosslinked chitosan membranes. *Journal of Applied Polymer Science*, **2007**, 106(6),
659 3884-3888. doi:10.1002/app.26920
- 660 50. Wen, H., & Park, K. Oral controlled release formulation design and drug delivery: theory to
661 practice. Hoboken, NJ: Wiley, **2010**, pp. 139-146. doi: 10.1002/9780470640487
- 662 51. Chen, Y., Lam, J. W., Kwok, R. T., Liu, B., Tang, B. Z. Aggregation-induced emission:
663 Fundamental understanding and future developments. *Materials Horizons*, **2019**, 6(3), 428-433.
664 doi:10.1039/c8mh01331d

- 665 52. Mansur, H. S., Sadahira, C. M., Souza, A. N., Mansur, A. A. FTIR spectroscopy
666 characterization of poly (vinyl alcohol) hydrogel with different hydrolysis degree and
667 chemically crosslinked with glutaraldehyde. *Materials Science and Engineering: C*, **2008**,
668 28(4), 539–548. doi: 10.1016/j.msec.2007.10.088
- 669 53. Pawlak, A., Mucha, M. Thermogravimetric and FTIR studies of chitosan blends.
670 *Thermochimica Acta*, **2003**, 396(1-2), 153–166. doi: 10.1016/s0040-6031(02)00523-3
- 671 54. Cardenas, G., Miranda, S. P. Ftir And Tga Studies Of Chitosan Composite Films. *Journal of*
672 *the Chilean Chemical Society*, **2004**, 49(4). doi: 10.4067/s0717-97072004000400005
- 673 55. Wang, G., Li, P. W., Peng, Z., Huang, M. F., Kong, L. X. Formulation of Vanillin Cross-
674 Linked Chitosan Nanoparticles and its Characterization. *Advanced Materials Research*, **2011**,
675 335-336, 474–477. doi: 10.4028/www.scientific.net/amr.335-336.474
- 676 56. Shekarforoush, E., Mendes, A., Baj, V., Beeren, S., Chronakis, I. Electrospun Phospholipid
677 Fibers as Micro-Encapsulation and Antioxidant Matrices. *Molecules*, **2017**, 22(10), 1708. doi:
678 10.3390/molecules22101708
- 679 57. Srithongkham, S., Sutcharee, P., Lertworasirikul, A. Investigation of Synthesis Parameters for
680 Modification of Chitosan with Enrofloxacin. *Key Engineering Materials*, **2015**, 659, 436–440.
681 doi: 10.4028/www.scientific.net/kem.659.436
- 682 58. Kumar, G. P., Phani, A., Prasad, R., Sanganal, J. S., Manali, N., Gupta, R., Raju, D., et al.
683 Polyvinylpyrrolidone oral films of enrofloxacin: Film characterization and drug release.
684 *International Journal of Pharmaceutics*, **2014**, 471(1-2), 146–152.
685 doi:10.1016/j.ijpharm.2014.05.033
- 686 59. Martinez, Y. N., Piñuel, L., Castro, G. R., & Breccia, J. D. Polyvinyl Alcohol–Pectin Cryogel
687 Films for Controlled Release of Enrofloxacin. *Applied Biochemistry and Biotechnology*, **2012**,
688 167(5), 1421–1429. doi: 10.1007/s12010-012-9554-6
- 689 60. Alves, N. O., Silva, G. T. D., Weber, D. M., Luchese, C., Wilhelm, E. A., Fajardo, A. R.
690 Chitosan/poly(vinyl alcohol)/bovine bone powder biocomposites: A potential biomaterial for
691 the treatment of atopic dermatitis-like skin lesions. *Carbohydrate Polymers*, **2016**, 148, 115–
692 124. doi: 10.1016/j.carbpol.2016.04.049
- 693 61. Casey, L. S., & Wilson, L. D. Investigation of Chitosan-PVA Composite Films and Their
694 Adsorption Properties. *Journal of Geoscience and Environment Protection*, **2015**, 03(02), 78–
695 84. doi: 10.4236/gep.2015.32013
- 696 62. Wu, H., Lei, Y., Lu, J., Zhu, R., Xiao, D., Jiao, C., Li, M. Effect of citric acid induced
697 crosslinking on the structure and properties of potato starch/chitosan composite films. *Food*
698 *Hydrocolloids*, **2019**, 97, 105208. doi:10.1016/j.foodhyd.2019.105208
- 699 63. Wahba, M. I. Enhancement of the mechanical properties of chitosan. *Journal of Biomaterials*
700 *Science, Polymer Edition*, **2019**, 31(3), 350-375. doi:10.1080/09205063.2019.1692641
- 701 64. Narasagoudr, S. S., Hegde, V. G., Vanjeri, V. N., Chougale, R. B., Masti, S. P. Ethyl vanillin
702 incorporated chitosan/poly(vinyl alcohol) active films for food packaging applications.
703 *Carbohydrate Polymers*, **2020**, 236, 116049. doi:10.1016/j.carbpol.2020.116049
- 704 65. Koosha, M., Hamed, S. Intelligent Chitosan/PVA nanocomposite films containing black
705 CARROT anthocyanin and bentonite nanoclays with improved mechanical, thermal and
706 antibacterial properties. *Progress in Organic Coatings*, **2019**, 127, 338-347.
707 doi:10.1016/j.porgcoat.2018.11.028
- 708 66. Olewnik-Kruszkowska, E., Gierszewska, M., Jakubowska, E., Tarach, I., Sedlarik, V.,
709 Pummerova, M. Antibacterial films based on PVA and PVA–Chitosan modified With
710 Poly(Hexamethylene Guanidine). *Polymers*, **2019**, 11(12), 2093. doi:10.3390/polym11122093
- 711 67. Jagadish, R., Divyashree, K., Viswanath, P., Srinivas, P., Raj, B. Preparation of n-vanillyl
712 chitosan and 4-hydroxybenzyl chitosan and their physico-mechanical, optical, barrier, and
713 antimicrobial properties. *Carbohydrate Polymers*, **2012**, 87(1), 110-116.
714 doi:10.1016/j.carbpol.2011.07.024
- 715 68. Kumria, R., Nair, A. B., Goomber, G., Gupta, S. Buccal films of prednisolone with enhanced
716 bioavailability. *Drug Delivery*, **2014**, 23(2), 471–478. doi: 10.3109/10717544.2014.920058

- 717 69. Enin, H. A. A., Nabarawy, N. A. E., Elmonem, R. A. A. Treatment of Radiation-Induced Oral
718 Mucositis Using a Novel Accepted Taste of Prolonged Release Mucoadhesive Bi-medicated
719 Double-Layer Buccal Films. *AAPS PharmSciTech*, **2016**, 18(2), 563–575.
720 doi:10.1208/s12249-016-0533-z
- 721 70. Mozafari, M., Moztafzadeh, Jalali, Alhosseini, N., Asgari, Dodel, Kargozar., et al. Synthesis
722 and characterization of electrospun polyvinyl alcohol nanofibrous scaffolds modified by
723 blending with chitosan for neural tissue engineering. *International Journal of Nanomedicine*,
724 **2012**, 25. doi: 10.2147/ijn.s25376
- 725 71. Stroescu, M., Stoica-Guzun, A., Jipa, I. M. Vanillin release from poly(vinyl alcohol)-bacterial
726 cellulose mono and multilayer films. *Journal of Food Engineering*, **2013**, 114(2), 153–157. doi:
727 10.1016/j.jfoodeng.2012.08.023
- 728 72. Vimala, K., Mohan, Y. M., Sivudu, K. S., Varaprasad, K., Ravindra, S., Reddy, N. N.,
729 Mohanaraju, K., et al. Fabrication of porous chitosan films impregnated with silver
730 nanoparticles: A facile approach for superior antibacterial application. *Colloids and Surfaces*
731 *B: Biointerfaces*, **2010**, 76(1), 248–258. doi: 10.1016/j.colsurfb.2009.10.044
- 732 73. Bernal-Ballen, A., Lopez-Garcia, J.-A., Ozaltin, K. (PVA/Chitosan/Fucoidan)-Ampicillin: A
733 Bioartificial Polymeric Material with Combined Properties in Cell Regeneration and Potential
734 Antibacterial Features. *Polymers*, **2019**, 11(8), 1325. doi: 10.3390/polym11081325
- 735 74. Al-Dhubiab, B. E., Nair, A. B., Kumria, R., Attimarad, M., Harsha, S. Development and
736 evaluation of buccal films impregnated with selegiline-loaded nanospheres. *Drug Delivery*,
737 **2014**, 1–9. doi: 10.3109/10717544.2014.948644
- 738 75. Cui, Z., Zheng, Z., Lin, L., Si, J., Wang, Q., Peng, X., Chen, W. Electrospinning and
739 crosslinking of polyvinyl alcohol/chitosan composite nanofiber for transdermal drug delivery.
740 *Advances in Polymer Technology*, **2017**, 37(6), 1917–1928. doi: 10.1002/adv.21850
- 741 76. Al-Kassas, R., Wen, J., Cheng, A. E.-M., Kim, A. M.-J., Liu, S. S. M., Yu, J. Transdermal
742 delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in
743 mucoadhesive gel. *Carbohydrate Polymers*, **2016**, 153, 176–186.
744 doi:10.1016/j.carbpol.2016.06.096
- 745 77. Mathematical models of drug release. (2015). *Strategies to Modify the Drug Release from*
746 *Pharmaceutical Systems*, 63–86. doi: 10.1016/b978-0-08-100092-2.00005-9
- 747 78. Motiei, M., Sedlařík, V., Lucia, L. A., Fei, H., Münster, L. Stabilization of chitosan-based
748 polyelectrolyte nanoparticle cargo delivery biomaterials by a multiple ionic cross-linking
749 strategy. *Carbohydrate Polymers*, 2020, 231, 115709. doi: 10.1016/j.carbpol.2019.115709
- 750 79. Hezaveh, H., & Muhamad, I. I. Controlled drug release via minimization of burst release in pH-
751 response kappa-carrageenan/polyvinyl alcohol hydrogels. *Chemical Engineering Research and*
752 *Design*, **2013**, 91(3), 508–519. doi: 10.1016/j.cherd.2012.08.014